The role of the HER-2/neu oncogene in gynecologic cancers

被引：67

作者：

Cirisano, FD ^{[1
]}

Karlan, BY ^{[1
]}

机构：

[1] UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DEPT OBSTET & GYNECOL,DIV GYNECOL ONCOL,LOS ANGELES,CA 90048

来源：

JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION | 1996年 / 3卷 / 03期

关键词：

HER-2/neu; gynecologic cancer; tumor marker; gene-targeted therapy;

D O I：

10.1016/1071-5576(96)00001-9

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

OBJECTIVE: The HER-2/neu proto-oncogene (also known as c-erbB2, neu, and HER2) encodes a 185-kDa transmembrane glycoprotein with intrinsic tyrosine kinase activity that resembles the receptor for epidermal growth factor. Aberrant HER-2/neu protein overexpression occurs in human gynecologic adenocarcinomas, including those of the ovary, endometrium, breast, fallopian tube, and cervix, and is secondary to gene amplification and/or overexpression of the p185(HER2) protein. METHODS: A Medline literature search revealed numerous studies on HER-2/neu and tumor biology, cancer prognosis, and therapeutic targeting. We present a review of the literature pertinent to gynecologic malignancies. RESULTS: Overexpression of HER-2/neu was found to be a poor prognostic factor for survival from advanced-stage ovarian cancer, node-positive breast cancer, and endometrial cancer. Although a specific ligand has not been definitively identified, HER-2/neu may have unusually complex activation pathways because it can form both homodimeric and heterodimeric associations with other related receptor proteins. Preliminary findings suggest that serum HER-2/neu levels may be used as a tumor marker in a subset of patients with tumors that overexpress the HER-2/neu receptor. Receptor-targeted therapeutics currently being studied include the use of receptor antibodies, liposomally delivered antisense DNA, antigen-activated cytotoxic lymphocytes, and adenovirus-mediated E1A delivery to overexpressing tumor cells. CONCLUSION: HER-2/neu appears to play an important role in the biologic behavior of ovarian, endometrial, and breast cancers and holds potential as a target for oncogene-directed therapies.

引用

页码：99 / 105

页数：7

共 58 条

[11] TUMOR-MARKER TRENDS IN ASYMPTOMATIC WOMEN AT RISK FOR OVARIAN-CANCER - RELEVANCE FOR OVARIAN-CANCER SCREENING [J].

CANE, P ;

AZEN, C ;

LOPEZ, E ;

PLATT, LD ;

KARLAN, BY .

GYNECOLOGIC ONCOLOGY, 1995, 57 (02) :240-245

[12]

CARNEY W P, 1991, Journal of Tumor Marker Oncology, V6, P53

[13] HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY [J].

CARTER, P ;

PRESTA, L ;

GORMAN, CM ;

RIDGWAY, JBB ;

HENNER, D ;

WONG, WLT ;

ROWLAND, AM ;

KOTTS, C ;

CARVER, ME ;

SHEPARD, HM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4285-4289

[14]

CHAZIN VR, 1992, ONCOGENE, V7, P1859

[15]

CLARK GM, 1991, CANCER RES, V51, P944

[16] C-ERBB-2 ONCOGENE EXPRESSION IN OVARIAN-CANCER [J].

HALDANE, JS ;

HIRD, V ;

HUGHES, CM ;

GULLICK, WJ .

JOURNAL OF PATHOLOGY, 1990, 162 (03) :231-237

[17] HER-2/NEU EXPRESSION - A MAJOR PROGNOSTIC FACTOR IN ENDOMETRIAL CANCER [J].

HETZEL, DJ ;

WILSON, TO ;

KEENEY, GL ;

ROCHE, PC ;

CHA, SS ;

PODRATZ, KC .

GYNECOLOGIC ONCOLOGY, 1992, 47 (02) :179-185

[18] A HEPARIN-BINDING GROWTH-FACTOR SECRETED BY MACROPHAGE-LIKE CELLS THAT IS RELATED TO EGF [J].

HIGASHIYAMA, S ;

ABRAHAM, JA ;

MILLER, J ;

FIDDES, JC ;

KLAGSBRUN, M .

SCIENCE, 1991, 251 (4996) :936-939

[19]

HUANG SK, 1992, CANCER RES, V52, P6774

[20] GROWTH-FACTOR EXPRESSION IN NORMAL PERITONEUM OF PATIENTS WITH GYNECOLOGIC CARCINOMA [J].

JENNINGS, TS ;

DOTTINO, PR ;

MANDELL, JP ;

SEGNA, RA ;

KELLIHER, K ;

COHEN, CJ .

GYNECOLOGIC ONCOLOGY, 1994, 55 (02) :190-197

← 1 2 3 4 5 6 →